At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 11 enrolled
Drug / intervention
Laronidasedrug
Likely dose
Laronidase 0.58 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Administration of Intravenous Laronidase Following Allogeneic Transplantation for Hurler Syndrome
Masonic Cancer Center, University of Minnesota·interventional·Posted Jul 30, 2010·Updated Mar 20, 2020
In Brief
A Phase 1 clinical trial evaluating Laronidase for Hurler Syndrome. Completed, enrolled 11 participants across 1 site.
Detailed Summary
This is a single center pilot study in which Laronidase will be given weekly for two years in patients with Hurler syndrome, also known as mucopolysaccharide IH (MPS I, Hurler syndrome), that have previously been treated with an allogeneic transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHurler Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2010
Enrollment StartMay 2012
Primary CompletionMar 2016
TodayJul 2026
First PostedJul 30, 2010
Enrollment StartMay 29, 2012
Primary CompletionMar 4, 2016
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 15.9 years ago
Interventions
Laronidasedrug
Laronidase 0.58 mg/kg intravenously (IV) once a week for a maximum of 2 years